Bacterial endocarditis is a serious and potentially life-threatening infection of the inner lining of the heart chambers (endocardium) or heart valves. It occurs when bacteria enter the bloodstream and attach to damaged areas of the heart, forming infective masses known as vegetations. Common causative bacteria include Streptococcus and Staphylococcus species. Individuals with pre-existing heart conditions, such as damaged heart valves or congenital heart defects, are at an increased risk of developing bacterial endocarditis. The condition often presents with symptoms like fever, fatigue, chills, and heart murmurs. Diagnosis involves blood cultures and imaging studies like echocardiography. Bacterial endocarditis requires prompt and targeted antibiotic treatment to eliminate the infecting bacteria. In severe cases or when complications arise, surgical intervention may be necessary to repair or replace damaged heart valves. Preventive measures involve antibiotic prophylaxis before certain dental or medical procedures in individuals with high-risk conditions. However, recommendations for prophylaxis have evolved, and the decision is often based on individual patient factors. Timely diagnosis and appropriate management are crucial to improving outcomes and reducing the risk of complications associated with bacterial endocarditis.
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States
Title : Hypersensitivity and anti-SARS-COV-2 vaccination: A retrospective study of the year 2021 at the University Hospital Center of Tours (France)
Faure Quentin, The Savoie Metropolitan Hospital Center, France
Title : Targeting resistance: New 4-substituted pyrazolidine and isoxazolidine as antibiotics with interesting antimicrobial activities
Yousfi Tarek, Nationale Research for Biotechnology Research Center, Algeria